Anzeige
Mehr »
Montag, 27.10.2025 - Börsentäglich über 12.000 News
Das nächste Lila Sciences? Telescope Innovations ist das 30-Millionen-Dollar-Tor zu KI-gesteuerter Chemie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41BQ3 | ISIN: US15117F8804 | Ticker-Symbol: NV40
NASDAQ
24.10.25 | 22:00
4,000 US-Dollar
+6,67 % +0,250
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CELLECTAR BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
CELLECTAR BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur CELLECTAR BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.10.Cellectar Biosciences, Inc. - S-1, General form for registration of securities35
10.10.Cellectar Biosciences beschafft 5,8 Mio. US-Dollar über Optionsscheine71
07.10.Cellectar Biosciences enters into agreements to raise $5.8M62
07.10.Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million37
06.10.Cellectar Biosciences, Inc. - 8-K, Current Report18
06.10.Cellectar Biosciences, Inc.: Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) ...277Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM Expected...
► Artikel lesen
24.09.Cellectar Biosciences, Inc.: Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)76
CELLECTAR BIOSCIENCES Aktie jetzt für 0€ handeln
11.09.Cellectar Biosciences, Inc.: Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-22589
09.09.Cellectar Biosciences, Inc.: Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit49
14.08.Cellectar signals NDA submission for iopofosine I-131 in WM by early 2026 amid accelerated approval focus108
14.08.Cellectar Biosciences GAAP EPS of -$3.39 beats by $0.3172
14.08.Cellectar Biosciences, Inc. - 8-K, Current Report21
14.08.Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update395Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and...
► Artikel lesen
14.08.Cellectar Biosciences, Inc. - 10-Q, Quarterly Report20
13.08.Cellectar Biosciences Q2 2025 Earnings Preview38
13.08.A Peek at Cellectar Biosciences' Future Earnings21
02.07.Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option158
01.07.Cellectar Biosciences prices $6 million public offering81
01.07.Cellectar Biosciences preist öffentliches Angebot von 6 Millionen US-Dollar220
01.07.Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering42
Weiter >>
64 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,54